155 related articles for article (PubMed ID: 12234602)
1. Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line.
Arnould S; Guichard S; Hennebelle I; Cassar G; Bugat R; Canal P
Biochem Pharmacol; 2002 Oct; 64(8):1215-26. PubMed ID: 12234602
[TBL] [Abstract][Full Text] [Related]
2. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
Guichard S; Arnould S; Hennebelle I; Bugat R; Canal P
Anticancer Drugs; 2001 Oct; 12(9):741-51. PubMed ID: 11593056
[TBL] [Abstract][Full Text] [Related]
3. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
[TBL] [Abstract][Full Text] [Related]
4. Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro.
Tanaka R; Ariyama H; Qin B; Shibata Y; Takii Y; Kusaba H; Baba E; Mitsugi K; Harada M; Nakano S
Oncol Rep; 2005 Sep; 14(3):683-8. PubMed ID: 16077975
[TBL] [Abstract][Full Text] [Related]
5. Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines.
Makiyama A; Qin B; Uchino K; Shibata Y; Arita S; Isobe T; Hirano G; Kusaba H; Baba E; Akashi K; Nakano S
Anticancer Drugs; 2009 Feb; 20(2):123-30. PubMed ID: 19209029
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death.
Tassone P; Tagliaferri P; Galea E; Palmieri C; Bonelli P; Martelli ML; Tuccillo F; Turco MC; Venuta S
Eur J Cancer; 2002 May; 38(8):1141-7. PubMed ID: 12008204
[TBL] [Abstract][Full Text] [Related]
8. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
[TBL] [Abstract][Full Text] [Related]
10. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
Ikehata M; Ogawa M; Yamada Y; Tanaka S; Ueda K; Iwakawa S
Biol Pharm Bull; 2014; 37(1):67-73. PubMed ID: 24172061
[TBL] [Abstract][Full Text] [Related]
11. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
12. Cell cycle arrest by oxaliplatin on cancer cells.
William-Faltaos S; Rouillard D; Lechat P; Bastian G
Fundam Clin Pharmacol; 2007 Apr; 21(2):165-72. PubMed ID: 17391289
[TBL] [Abstract][Full Text] [Related]
13. Gene and protein expression in the oxaliplatin-resistant HT29/L-OHP human colon cancer cell line.
Xiang Z; Kang QJ; Xiang X
Genet Mol Res; 2015 Sep; 14(3):11013-22. PubMed ID: 26400331
[TBL] [Abstract][Full Text] [Related]
14. In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines.
Qin B; Tanaka R; Shibata Y; Arita S; Ariyama H; Kusaba H; Baba E; Harada M; Nakano S
Anticancer Drugs; 2006 Apr; 17(4):445-53. PubMed ID: 16550003
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of asiatic acid and CPT-11 on growth of HT-29 cells.
Bunpo P; Kataoka K; Arimochi H; Nakayama H; Kuwahara T; Vinitketkumnuen U; Ohnishi Y
J Med Invest; 2005 Feb; 52(1-2):65-73. PubMed ID: 15751275
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.
Temmink OH; Hoebe EK; van der Born K; Ackland SP; Fukushima M; Peters GJ
Br J Cancer; 2007 Jan; 96(2):231-40. PubMed ID: 17242697
[TBL] [Abstract][Full Text] [Related]
17. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.
Kanzawa F; Koizumi F; Koh Y; Nakamura T; Tatsumi Y; Fukumoto H; Saijo N; Yoshioka T; Nishio K
Clin Cancer Res; 2001 Jan; 7(1):202-9. PubMed ID: 11205910
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle arrest and apoptosis induced by oxaliplatin (L-OHP) on four human cancer cell lines.
William-Faltaos S; Rouillard D; Lechat P; Bastian G
Anticancer Res; 2006; 26(3A):2093-9. PubMed ID: 16827150
[TBL] [Abstract][Full Text] [Related]
19. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
Azzariti A; Xu JM; Porcelli L; Paradiso A
Biochem Pharmacol; 2004 Jul; 68(1):135-44. PubMed ID: 15183125
[TBL] [Abstract][Full Text] [Related]
20. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Miknyoczki SJ; Jones-Bolin S; Pritchard S; Hunter K; Zhao H; Wan W; Ator M; Bihovsky R; Hudkins R; Chatterjee S; Klein-Szanto A; Dionne C; Ruggeri B
Mol Cancer Ther; 2003 Apr; 2(4):371-82. PubMed ID: 12700281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
